公开(公告)号：US20240376222A1

公开(公告)日：2024-11-14

申请号：US18691125

申请日：2022-09-13

Applicant: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM

Inventor： Zhiqiang AN ,  Ningyan ZHANG ,  Peng ZHAO

IPC: C07K16/28 ,  A61K49/00 ,  C07K14/725

Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, antibodies, antibody fragments, etc., that specifically bind a TfR protein, e.g., a mammalian TfR or human TfR, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.

公开(公告)号：US20230235078A1

公开(公告)日：2023-07-27

申请号：US18176072

申请日：2023-02-28

Applicant: The BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM ,  THE GEORGE WASHINGTON UNIVERSITY

Inventor： Ningyan ZHANG ,  Zhiqiang AN ,  Hui DENG ,  Xiujie SUN ,  Rong LI

IPC: C07K16/28 ,  C12N15/63 ,  A61P35/00

CPC classification number: C07K16/2896 ,  C12N15/63 ,  A61P35/00 ,  C07K2317/20 ,  C07K2317/565

Abstract: The present disclosure relates to antibodies binding to tumor discoidin domain receptor 1 (DDR1) and the uses of the antibodies in detecting and treating cancer.

公开(公告)号：US20210349096A1

公开(公告)日：2021-11-11

申请号：US16321745

申请日：2017-07-27

Applicant: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM

Inventor： Chengcheng ZHANG ,  Zhiqiang AN ,  Ningyan ZHANG ,  Mi DENG ,  Jaehyup KIM ,  Xun GUI

IPC: G01N33/574 ,  G01N33/50 ,  G01N15/14 ,  G01N21/64

Abstract: Provided herein are methods and compositions for the identification of modulators of ApoE-induced LILRB activation. Also provided herein are methods of treating cancer comprising the administration of an inhibitor of ApoE-induced LILRB activation. Also provided are methods of treating autoimmune disease or inhibiting the onset of transplant rejection or treating an inflammatory disorder comprising administering an agonist of ApoE-induced LILRB activation to a subject.

公开(公告)号：US20240392001A1

公开(公告)日：2024-11-28

申请号：US18691249

申请日：2022-09-13

Applicant: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM

Inventor： Zhiqiang AN ,  Ningyan ZHANG ,  Peng ZHAO

IPC: C07K16/28

Abstract: Isolated or recombinant anti-LILRB2 monoclonal antibodies are provided. In some embodiments, the antibodies herein can be used for the detection, diagnosis and/or therapeutic treatment of human diseases, such as Alzheimer's Disease. In further aspects, the LILRB2-binding antibodies can affect cellular signaling mediated through at least the oA and PS-mediated TREM2 and LILRB2 co-ligation signaling pathway and can be used to modulate microglia function.

公开(公告)号：US20230130372A1

公开(公告)日：2023-04-27

申请号：US17757510

申请日：2020-12-17

Applicant: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM ,  THE GEORGE WASHINGTON UNIVERSITY

Inventor： Ningyan ZHANG ,  Zhiqiang AN ,  Hui DENG ,  Xiujie SUN ,  Rong LI

IPC: C07K16/28 ,  C12N15/63 ,  A61P35/00

Abstract: The present disclosure relates to antibodies binding to tumor discoidin domain receptor 1 (DDR1) and the uses of the antibodies in detecting and treating cancer. Thus, in one aspect, the present disclosure provides an isolated monoclonal antibody or an antigen-binding fragment thereof that binds specifically to DDR1. In certain embodiments, the antibody or antigen-binding fragment, when bound to DDR1, modulates the activity of DDR1, i.e., suppresses DDR1.

公开(公告)号：US20220267415A1

公开(公告)日：2022-08-25

申请号：US17671837

申请日：2022-02-15

Applicant: The Board of Regents of The University of Texas System ,  IGM Biosciences, Inc.

Inventor： Zhiqiang KU ,  Xuping XIE ,  Paul HINTON ,  Ningyan ZHANG ,  Bruce KEYT ,  Dean NG ,  Stephen CARROLL ,  Pei-Yong SHI ,  Zhiqiang AN

IPC: C07K16/10 ,  A61P31/14

Abstract: This disclosure provides multimeric binding molecules that bind to SARS-CoV-2. This disclosure also provides compositions comprising the multimeric binding molecules, polynucleotides that encode the multimeric binding molecules, and host cells that can produce the binding molecules. Further this disclosure provides methods of using the multimeric binding molecules, including methods for treating and preventing coronavirus disease 2019 (COVID-19).

公开(公告)号：US20190338026A1

公开(公告)日：2019-11-07

申请号：US16475223

申请日：2018-01-02

Applicant: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM

Inventor： X. Charlene LIAO ,  Qiang LIU ,  Zhiqiang AN ,  Ningyan ZHANG ,  Xun GUI ,  Chengcheng ZHANG ,  Mi DENG ,  Jingjing XIE

IPC: C07K16/28 ,  C12N5/12 ,  C12N15/85

Abstract: The present disclosure is directed to antibodies binding to LAIR 1 and their treating cancer, inflammation, immune-related diseases or transplantation.

公开(公告)号：US20230399384A1

公开(公告)日：2023-12-14

申请号：US17996874

申请日：2021-04-22

Applicant: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM

Inventor： Zhiqiang KU ,  Ningyan ZHANG ,  Zhiqiang AN ,  Xuping XIE ,  Pei-Yong SHI

IPC: C07K16/10 ,  A61P31/14

CPC classification number: C07K16/1003 ,  A61P31/14 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/34 ,  A61K2039/505

Abstract: Provided herein are antibodies binding to Coronavirus S protein and the uses of the antibodies in detecting and treating Coronavirus infection, such as COVID-19.

公开(公告)号：US20230348586A1

公开(公告)日：2023-11-02

申请号：US18026696

申请日：2021-09-21

Applicant: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM

Inventor： Phillipp E. SCHERER ,  Shangang ZHAO ,  Zhiqiang AN ,  Ningyan ZHANG

IPC: C07K16/26 ,  A61K38/46 ,  A61K31/7088 ,  A61K38/22 ,  C12N15/113 ,  A61K38/26 ,  A61K39/395 ,  A61P3/04 ,  A61P35/02 ,  A61P35/00 ,  A61P9/00 ,  A61P1/16

CPC classification number: C07K16/26 ,  A61K38/465 ,  A61K31/7088 ,  A61K38/2264 ,  C12N15/1136 ,  A61K38/26 ,  A61K39/3955 ,  A61P3/04 ,  A61P35/02 ,  A61P35/00 ,  A61P9/00 ,  A61P1/16 ,  C12N2310/14 ,  C12N2310/531 ,  A61K2039/505

Abstract: The present disclosure relates generally to therapeutic agents and related uses thereof, including, agents for reducing leptin in a patient or subject and methods of treatment thereof. The therapeutic agents can comprise (without limitation), an antibody or specific binding fragment thereof, a leptin antagonist, a leptin targeting antisense oligonucleotide, a leptin targeting small interfering RNA (siRNA), a leptin targeting short hairpin RNA (shRNA), and/or a gene editing composition directed to at least one target sequence of a leptin polynucleotide. The therapeutic agents can be used in various methods of treatment, including (without limitation), treating liver fibrosis, cancer, inducing or maintaining weight loss, reducing or preventing weight gain, and increasing insulin sensitivity, among others.

公开(公告)号：US20210179687A1

公开(公告)日：2021-06-17

申请号：US16762273

申请日：2018-11-06

Applicant: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM

Inventor： Chengcheng ZHANG ,  Samuel JOHN ,  Heyu CHEN ,  Mi DENG ,  Xun GUI ,  Ningyan ZHANG ,  Zhiqiang AN

IPC: C07K14/705 ,  A61K45/06 ,  A61P35/02 ,  C12N5/0783

Abstract: The present disclosure provides methods and compositions for immunotherapy employing a modified T cell or NK cell comprising a chimeric LILRB4 antigen receptor (CAR) that can be administered to patients for disease (e.g., cancer) treatment.